In this task, you are given a abstract of article and corresponding title of an article. Your task is to generate label "yes" if title is right for article, otherwise generate "no".

[EX Q]: Abstract: The p75(NTR) neurotrophin receptor has been implicated in multiple biological and pathological processes. While significant advances have recently been made in understanding the physiologic role of p75(NTR) , many details and aspects remain to be determined. This is in part because the two existing knockout mouse models (Exons 3 or 4 deleted, respectively), both display features that defy definitive conclusions. Here we describe the generation of mice that carry a conditional p75(NTR) (p75(NTR-FX) ) allele made by flanking Exons 4-6, which encode the transmembrane and all cytoplasmic domains, by loxP sites. To validate this novel conditional allele, both neural crest-specific p75(NTR) /Wnt1-Cre mutants and conventional p75(NTR) null mutants were generated. Both mutants displayed abnormal hind limb reflexes, implying that loss of p75(NTR) in neural crest-derived cells causes a peripheral neuropathy similar to that seen in conventional p75(NTR) mutants. This novel conditional p75(NTR) allele will offer new opportunities to investigate the role of p75(NTR) in specific tissues and cells.. Title: Identification of indole-3-carboxylic acid as mediator of priming against Plectosphaerella cucumerina.
[EX A]: no

[EX Q]: Abstract: Lung cancer is the leading cause of cancer-related mortality in humans worldwide. Moreover, the overall 5-year survival rate is only 15%. Pathologically almost 80% of all lung cancer cases are non-small cell lung cancer (NSCLC). Cancer-associated fibroblasts (CAFs) have been found to exist in a large number of NSCLCs. CAFs have been proven to promote tumor progression, metastasis and resistance to therapy through paracrine effects in most solid tumors. In the present study, firstly we isolated CAFs from patient tissues and demonstrated that they promoted cell proliferation and chemoresistance to cisplatin in the lung cancer cell lines A549 and 95D in a paracrine manner. Secondly, using ELISA and quantative PCR, we found that a higher amount of stromal cell-derived factor 1 (SDF-1) existed in the CAFs rather than that observed in the normal fibroblasts (NFs). Thirdly, we detected that SDF-1 facilitated lung cancer cell proliferation and drug resistance via the CXCR4-mediated signaling pathway which involved NF-B and Bcl-xL. Moreover, we also confirmed that the expression level of SDF-1 in the CAFs was negatively regulated by microRNA mir-1 through microRNA overexpression and quantitative PCR. Overall, our data provide one explanation for the effects of CAFs on lung cancer cells. Meanwhile, our results also suggest CAFs as a potential therapeutic target in tumor treatment.. Title: Trends in sugar-sweetened beverage consumption among youth and adults in the United States: 1999-2010.
[EX A]: no

[EX Q]: Abstract: Summary Sample-size determination is often an important step in planning an epidemiological study. There are several approaches to determining sample size. It depends on the type of the study. Descriptive, observational and randomized controlled studies have different formulas to calculate sample size. In this article, we discuss the formulas that can help to estimate sample size in an epidemiological trial. We present a few examples from clinical practice, which may contribute to the understanding of this problem. Keywords: sample size determination Determining an appropriate sample size for a clinical trial is an essential step in the statistical design of the pro-ject. An adequate sample size helps ensure that the stu-dy will yield reliable information, regardless of whether the ultimate data suggest a clinically important difference between the treatments being studied, or the study is in-tended to measure the accuracy of a diagnostic test or the incidence of a disease. Unfortunately, many studies pub-lished in medical literature are conducted with inadequate sample sizes, making the interpretation of negative results difficult. Conductingastudywithaninadequatesamplesize is not only futile, it is also unethical. Exposing pa-tients to the risks inherent in a research is justifiableon-ly if there is a realistic possibility that the results will be-nefitthosesubjects,futuresubjects,orleadtosubstantialscientificprogress. How many individuals will I need to study? This ques-tion iscommonly asked by a clinical investigator and ex-poses oneof many issues that are best to be settled before actually carryingout a study. Consultation with a statisti-cian is worthwhilein addressing many issues of study de-sign, but a statisticianis not always readily available. Sample Size (n) is the number of individuals in a group under study. The larger the sample size, the grea-ter the precision and, thus, power for a given study de-sign to detect an effect of a given size. For statisticians, an n > 30 is usually sufficientfortheCentralLimitTheo-rem to hold so that normal theory approximations can be used for measures such as the standard error of the mean. However, this sample size (n = 30) is unrelated to the cli-nicians' objective of detecting biologically significantef-fects, which determines the specificsamplesizeneededfor a specificstudy[1].. Title: Sample size calculation in epidemiological studies
[EX A]:
yes